Dose, Effects and Characteristics of Pilocarpine

The purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: Part I - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. Part II -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when given once, twice and four daily. In addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Wills Eye Glaucoma Service

Philadelphia, Pennsylvania, 19107, United States

About this study

In addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Primary open-angle glaucoma
Primary open-angle glaucoma suspect

Treatment and study plan

Pilocarpine Concentration

Drug

Varying concentration 0.5 to 8%

Pilocarpine Frequency

Drug

1 to 4 times daily

Primary outcomes

Intraocular Pressure

Time frame: 25 days

Sponsors and collaborators

Lead sponsor

Wills Eye

Other

Registry information

Important dates

Study start: 1978
Primary completion: 1979
Study completion: 1979
First posted: Dec 8, 2008
Registry last updated: Nov 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed